Literature DB >> 10452099

Alpha-momorcharin inhibits HIV-1 replication in acutely but not chronically infected T-lymphocytes.

Y T Zheng1, K L Ben, S W Jin.   

Abstract

AIM: To identify the anti-human immunodeficiency virus type 1 (HIV-1) activities of alpha-momorcharin (alpha-MMC) from Momordica charantia in acutely and chronically infected T-lymphocytes.
METHODS: The anti-HIV activities of alpha-MMC were examined by 1) the inhibition of syncytia formation induced by HIV-1 III B; 2) reduction of p24 core antigen expression level and decrease in numbers of HIV antigen positive cells in acutely and chronically infected cultures. The cytotoxic effects of alpha-MMC was tested by trypan blue dye exclusion or colorimetric MTT assay.
RESULTS: alpha-MMC was found to obviously inhibit HIV-1 III B-inducing C8166 syncytia formation and markedly reduced both expression of p24 core antigen and the numbers of HIV antigen positive cells in acutely but not chronically HIV-1-infected culture. The median effective concentration (EC50) in these assays were 0.016, 0.07, and 0.32 mg.L-1, respectively.
CONCLUSION: alpha-MMC is a unique component of momorcharin with anti-HIV activity, and markedly inhibited HIV-1 replication in acutely but not chronically HIV-1-infected T-lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452099

Source DB:  PubMed          Journal:  Zhongguo Yao Li Xue Bao        ISSN: 0253-9756


  2 in total

1.  Inhibitory effects of crude extracts from some edible Thai plants against replication of hepatitis B virus and human liver cancer cells.

Authors:  Wanwisa Waiyaput; Sunchai Payungporn; Jiraphorn Issara-Amphorn; Nattanan T-Thienprasert Panjaworayan
Journal:  BMC Complement Altern Med       Date:  2012-12-06       Impact factor: 3.659

2.  Inhibition of HIV-1 replication by balsamin, a ribosome inactivating protein of Momordica balsamina.

Authors:  Inderdeep Kaur; Munish Puri; Zahra Ahmed; Fabien P Blanchet; Bastien Mangeat; Vincent Piguet
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.